A5074758454- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Medical Imaging Techniques and Applications
- Functional Brain Connectivity Studies
- Advanced MRI Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
- Neurotransmitter Receptor Influence on Behavior
- Down syndrome and intellectual disability research
- Neuroscience and Neuropharmacology Research
- Sleep and Wakefulness Research
- Frailty in Older Adults
- Radiomics and Machine Learning in Medical Imaging
- Cerebrovascular and Carotid Artery Diseases
- Neurological Disease Mechanisms and Treatments
- Sleep and related disorders
- Eating Disorders and Behaviors
- Obsessive-Compulsive Spectrum Disorders
- MRI in cancer diagnosis
- Chronic Disease Management Strategies
- Diet and metabolism studies
- Treatment of Major Depression
- Lanthanide and Transition Metal Complexes
- Adipose Tissue and Metabolism
- Patient Safety and Medication Errors
- Radiopharmaceutical Chemistry and Applications
Athinoula A. Martinos Center for Biomedical Imaging
2018-2025
Massachusetts General Hospital
2017-2025
Harvard University
2016-2025
Gordon Center for Medical Imaging
2021-2025
Massey University
2024
Dunedin Public Hospital
2024
University of Waikato
2024
University of Otago
2024
Cardiff University
2024
Charles River Associates
2024
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared controls, typically showed marked retention PIB areas association cortex known to contain large amounts amyloid deposits AD. In patient group, was increased most prominently frontal (1.94-fold, p = 0.0001). Large increases also were observed parietal (1.71-fold, 0.0002), temporal...
<b>Objective: </b> To compare brain β-amyloid (Aβ) burden measured with [<sup>11</sup>C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias. <b>Methods: Thirty-three subjects dementia (17 AD, 10 Lewy bodies [DLB], 6 frontotemporal [FTD]), 9 mild cognitive impairment (MCI), 27 age-matched healthy control (HCs) were studied. Aβ was quantified using PIB distribution volume ratio. <b>Results: Cortical binding markedly elevated every AD subject regardless...
Objective: To characterize the prevalence of amyloid deposition in a clinically unimpaired elderly population, as assessed by Pittsburgh Compound B (PiB) positron emission tomography (PET) imaging, and its relationship to cognitive function, measured with battery neuropsychological tests.Design: Subjects underwent testing PiB PET imaging (15 mCi for 90 minutes an ECAT HRϩ scanner).Logan graphical analysis was applied estimate regional retention distribution volume, normalized cerebellar...
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to β-pleated sheet aggregates of the amyloid-β (Aβ) peptide in vitro. vivo retention PiB brains people Alzheimer's disease shows a regional distribution that is very similar Aβ deposits observed post-mortem. However, basis for variations binding vivo, and extent which it different types Aβ-containing plaques tau-containing neurofibrillary tangles (NFT), has not been thoroughly...
Abstract Although amyloid imaging with PiB‐PET ([C‐11]Pittsburgh Compound‐B positron emission tomography), and now F‐18‐labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there been considerable variability in the exact numbers reported as quantitative outcome measures tracer retention. In some cases this is trivial choice units, it scanner dependent, course, different tracers yield numbers. Our working group was formed to standardize...
Fibrillar amyloid-beta (Abeta) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) unknown. We used Pittsburgh Compound B (PiB) PET characterize relationship between fibrillar Abeta burden and people at 3 mean levels genetic risk for AD. Dynamic PiB scans, Logan method, statistical parametric mapping, automatically labeled regions interest (ROIs) were compare cerebral-to-cerebellar PIB distribution volume...
OBJECTIVE: The authors investigated the neurobiological basis of poor sleep and daytime fatigue in insomnia. METHOD: [18F]Fluorodeoxyglucose positron emission tomography was used to assess regional cerebral glucose metabolism seven patients with insomnia 20 healthy subjects. RESULTS: Compared subjects, showed greater global during while awake, a smaller decline relative from waking states wake-promoting regions, reduced prefrontal cortex awake. CONCLUSIONS: Subjectively disturbed is...
A valid quantitative imaging method for the measurement of amyloid deposition in humans could improve Alzheimer's disease (AD) diagnosis and antiamyloid therapy assessment. Our group developed Pittsburgh Compound-B (PIB), an amyloid-binding radiotracer, positron emission tomography (PET). The current study was aimed to further validate PIB PET through (arterial input) inclusion subjects with mild cognitive impairment (MCI). studies were performed five AD, MCI, control retested within 20...
Background This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core. Methods The Core has supervised acquisition, quality control, and analysis longitudinal [ 18 F]fluorodeoxyglucose PET (FDG‐PET) data in approximately half ADNI cohort. In an “add on” study, 100 subjects also underwent scanning with 11 C] Pittsburgh compound B for amyloid imaging. developed control procedures standardized image acquisition by developing...
Abstract Objective Cerebrovascular deposition of β‐amyloid (cerebral amyloid angiopathy [CAA]) is a major cause hemorrhagic stroke and likely contributor to vascular cognitive impairment. We evaluated positron emission tomographic imaging with the β‐amyloid–binding compound Pittsburgh Compound B (PiB) as potential noninvasive method for detection CAA. hypothesized that would be observed PiB in CAA, based on occipital predilection CAA pathology associated hemorrhages, specific retention...
<b>Background:</b> PET imaging using [<sup>18</sup>F]fluorodeoxyglucose (FDG) and [<sup>11</sup>C]Pittsburgh compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), CSF measures the 42 amino acid β-amyloid protein (Aβ<sub>1-42</sub>) total phosphorylated tau (t-tau p-tau). Relationships between with severity are incompletely understood. <b>Methods:</b> Ten subjects AD, 11 control subjects, 34 mild cognitive impairment from Alzheimer’s Disease Neuroimaging Initiative...
The amyloid cascade hypothesis suggests that the aggregation and deposition of amyloid-β protein is an initiating event in Alzheimer9s disease (AD). Using imaging technology, such as positron emission tomography (PET) agent Pittsburgh compound-B (PiB), it possible to explore natural history preclinical people at high risk for AD. With this goal mind, asymptomatic (<i>n</i> = 5) symptomatic carriers presenilin-1 (PS1) mutations (C410Y or A426P) lead early-onset AD noncarrier controls from...
During the development of in vivo amyloid imaging agents, an effort was made to use micro-positron emission tomography (PET) presenilin-1 (PS1)/amyloid precursor protein (APP) transgenic mouse model CNS deposition screen new compounds and further study Pittsburgh Compound-B (PIB), a PET tracer that has been shown be retained well amyloid-containing areas Alzheimer's disease (AD) brain. Unexpectedly, we saw no significant retention PIB this even at 12 months age when PS1/APP typically exceeds...
We utilized the amyloid imaging ligand Pittsburgh Compound B (PiB) to determine presence of Alzheimer's disease (AD) pathology in different mild cognitive impairment (MCI) subtypes and relate increased PiB binding other markers early AD longitudinal outcome.
<h3>Importance</h3> Mounting evidence suggests that sex differences exist in the pathologic trajectory of Alzheimer disease. Previous literature shows elevated levels cerebrospinal fluid tau women compared with men as a function apolipoprotein E (APOE) ε4 status and β-amyloid (Aβ). What remains unclear is association regional deposition clinically normal individuals. <h3>Objective</h3> To examine cross-sectional between Aβ measured positron emission tomography (PET). <h3>Design, Setting...
In vivo and autopsy evidence supports locus coeruleus MRI measures as proxy of initial TAU deposition amyloid-related memory decline.
Advances in molecular positron emission tomography (PET) have enabled anatomic tracking of brain pathology longitudinal studies normal aging and dementia, including assessment the central model Alzheimer's disease (AD) pathogenesis, according to which TAU begins focally but expands catastrophically under influence amyloid-β (Aβ) mediate neurodegeneration cognitive decline. Initial deposition occurs many years before Aβ a specific area medial temporal lobe. Building on recent work that focus...